[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"oxaliplatin\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:oxaliplatin":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,44,73,104,131],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":5},"100621123","phase-3-adjuvant-oxaliplatin-plus-s-1-versus-docetaxel-plus-s-1-for-stage-iii-gastric-cancer-100621123",false,"NCT07366528","Adjuvant Oxaliplatin Plus S-1 Versus Docetaxel Plus S-1 for Stage III Gastric Cancer","Adjuvant Oxaliplatin Plus S-1 Versus Docetaxel Plus S-1 for Stage III Gastric Cancer After D2 Gastrectomy (DRAGON-Adjuvant): a Multicenter, Open-label, Phase 3, Randomized, Non-inferiority Study","Inclusion Criteria:\n\n1. age 18 to 80 years old, male and female\n2. histologically confirmed adenocarcinoma of the stomach or gastroesophageal junction\n3. patients underwent standard D2 gastrectomy and achieved R0 resection, and had no systemic therapy like neoadjuvant therapy\n4. American Joint Committee on Cancer stage IIIA (T2N3a, T3N2, T4aN1, T4aN2, T4bN0), IIIB (T1N3b, T2N3b, T3N3a, T4aN3a, T4bN1, T4bN2), IIIC (T3N3b, T4aN3b, T4bN3a, T4bN3b), and has Lauren classification\n5. with no evidence of metastatic disease\n6. ECOG 0 to 1\n7. Enough organ functions that can tolerate treatment: Absolute neutrophil count (ANC) ≥1.5x109\u002FL, White blood count ≥3.5x109\u002FL, Platelets ≥75x109\u002FL, Hemoglobin (Hb) ≥80g\u002FL, ALT\u002FAST ≤2.5x ULN (for patient with liver metastasis ALT\u002FAST ≤5x ULN), Serum bilirubin ≤1.5x ULN, Serum creatinine ≤1.5x ULN.\n8. Woman of childbearing age should contracept for at least one month before screening and commit to using contraception throughout the entire study period and for the specified time after the study ends.\n9. Signed informed consent and willing to follow the study protocol\n\nExclusion Criteria:\n\n1. other primary malignancies, except for cured skin tumors or cervical carcinoma in situ\n2. severe complications that may lead to an expected survival time less than 5 years\n3. uncontrollable comorbidities, such as infectious disease, chronic diseases like hypertension, diabetes, heart diseases.\n4. allergic to study medication\n5. bowel obstruction or other conditions affecting oral administration\n6. organ functions that cannot tolerate study treatment\n7. other conditions that patients are unsuitable for this study assessed by the investigators","ALL","18 Years","80 Years",{"count":20,"type":21},387,"ESTIMATED","INTERVENTIONAL",[24],"PHASE3","This is a multicenter, open-label, phase 3, randomized, non-inferiority study aimed to investigate the effect on disease-free survival of adjuvant chemotherapy with oxaliplatin plus S-1 compared with adjuvant chemotherapy with docetaxel plus S-1 after D2 gastrectomy in patients with stage III gastric cancer.",[27,28,29,30,31],"Gastric Cancer (GC)","Adjuvant Chemotherapy","Stage 3 Cancer","Docetaxel","Oxaliplatin","RECRUITING","2026-01-16",{"date":35,"type":36},"2026-01-26","ACTUAL",{"date":38,"type":36},"2025-12-15",{"date":40,"type":21},"2030-10-31",{"name":42,"class":43},"Ruijin Hospital","OTHER",{"id":45,"slug":46,"hasResults":11,"nctId":47,"briefTitle":48,"officialTitle":49,"acronym":4,"eligibilityCriteria":50,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":51,"enrollmentInfo":52,"targetDuration":4,"studyType":22,"phases":54,"briefSummary":56,"conditions":57,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":72},"100510009","phase-2-lenvatinib-combined-with-tislelizumab-and-tace-applied-as-neoadjuvant-regimen-for-the-patients-of-cnlc-stage-ib-and-iia-hepatocellular-carcinoma-with-high-risk-recurrence-factors-100510009","NCT05920863","Lenvatinib Combined with Tislelizumab and TACE Applied As Neoadjuvant Regimen for the Patients of CNLC Stage IB and IIA Hepatocellular Carcinoma with High-risk Recurrence Factors","Lenvatinib Combined with Tislelizumab and TACE Applied As Neoadjuvant Regimen for the Patients of CNLC Stage IB and IIA Hepatocellular Carcinoma with High Risk of Recurrence: Study Protocol of a Monocenter, Single-arm, Open Label Clincal Trail","Inclusion Criteria:\n\n1. Aged 18-75 years old (inclusive);\n2. HCC is confirmed by preoperative pathological examination or meet the criterion of diagnosis and treatment norms of primary HCC issued by health commission, PRC. No prior systemic chemotherapy, immunotherapy, targeted therapy, or other anti-tumor treatments for HCC;\n3. Patients with CNLC IB or IIA stage tumors before surgery and meeting the following conditions: radiological evaluation shows narrow or none surgical margins, and preoperative tumor markers AFP+PIVKA is greater than 1600.\n4. ECOG score of 0 before the first administration of the study drug;\n5. Child-Pugh scores is 5-6 points and liver function is grade A;\n6. Expected survival time of at least 16 weeks;\n7. Pre-administration organ function levels meet the requirements and are tolerant of surgery. The functional indicators of important organs meet the following requirements: hemoglobin ≥90g\u002FL, neutrophil count ≥1.5×10⁹\u002FL, platelet count ≥100×10⁹\u002FL; aspartate aminotransferase or alanine aminotransferase ≤5 times the upper limit of normal (ULN), alkaline phosphatase ≤2.5 ULN, serum albumin ≥30g\u002FL; serum creatinine \\\u003C1.5 ULN; international normalized ratio (INR) ≤2 or prothrombin time (PT) within the upper limit of normal range ≤6 seconds; serum creatinine ≤1.5 ULN, creatinine clearance rate ≥60 mL\u002Fmin.\n8. Male and female participants of childbearing potential must agree to use effective contraception throughout the study period;\n9. Sign an informed consent form and agree to provide previously stored tumor tissue specimens or fresh biopsy specimens of the tumor lesion.\n\nExclusion Criteria:\n\n1. Pathologically diagnosed as non-hepatocellular carcinoma;\n2. Previously received anti-tumor treatments such as chemotherapy, radiotherapy, radiofrequency ablation, intervention, targeted therapy, immunotherapy or surgical treatment for liver cancer (excluding previous non-tumor-related surgery or diagnostic biopsy);\n3. CNLC stage is IA, IIB or worse.\n4. Viral load limited to hepatitis B virus (HBV) DNA\\>2000 copies\u002Fml, hepatitis C virus (HCV) RNA\\>1000;\n5. Long-term steroid users who require long-term systemic steroid therapy (equivalent to \\>10 mg of prednisone per day) or any other form of immunosuppressive treatment;\n6. Significant clinical bleeding or bleeding tendency within 3 months before enrollment or currently undergoing thrombolysis or anticoagulation treatment;\n7. Complete intestinal obstruction and incomplete intestinal obstruction requiring treatment, but patients who have had obstruction relieved by fistula or stent placement can be enrolled;\n8. Active severe clinical infection (\\> grade 2, NCI-CTCAE version 5.0), including active tuberculosis; history of active tuberculosis infection for more than 1 year before enrollment, not treated with regular anti-tuberculosis treatment or tuberculosis still in the active period; active known or suspected autoimmune disease;\n9. Uncontrolled diabetes (fasting blood glucose ≥10 mmol\u002FL), severe lung disease (such as acute pulmonary disease, pulmonary fibrosis that affects lung function, interstitial lung disease. Excluding recovered radiation pneumonitis);\n10. Clinically significant cardiovascular disease; hypertension which cannot be well controlled by anti-hypertensive drugs (systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg);\n11. Patients undergoing renal replacement therapy;\n12. History of other malignant tumors within the past 5 years. Excluding cured basal cell carcinoma or cervical intraepithelial neoplasia;\n13. Other patients who are expected to be unable to tolerate surgical treatment;\n14. Patients who have had allergic reactions to any component of the study drug;\n15. Presence of alcohol dependence, mental illness, pregnancy (or lactation) or other conditions that are not suitable for clinical trials.","75 Years",{"count":53,"type":21},35,[55],"PHASE2","This is a monocenter, single-arm, open-label study to evaluate the efficacy and safety of Lenvatinib combined with Tislelizumab and TACE applied as neoadjuvant regimen for the patients of CNLC stage IB and IIA hepatocellular carcinoma with high risk of recurrence Primary outcome: Major pathological response (MPR) Secondary outcomes: pathological complete response (pCR), R0 resection rate, objective response rate (ORR), disease control rate (DCR), treatment-related adverse events (TRAE)",[58,59,60,61,62,31],"Hepatocellular Carcinoma","Lenvatinib","Tislelizumab","TACE","Pharmorubicin","2025-02-09",{"date":65,"type":36},"2025-02-11",{"date":67,"type":36},"2023-07-01",{"date":69,"type":21},"2025-12-31",{"name":71,"class":43},"Zhejiang Cancer Hospital",1,{"id":74,"slug":75,"hasResults":11,"nctId":76,"briefTitle":77,"officialTitle":78,"acronym":4,"eligibilityCriteria":79,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":80,"targetDuration":4,"studyType":22,"phases":82,"briefSummary":83,"conditions":84,"keywords":92,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":95,"lastUpdatePostDateStruct":96,"startDateStruct":98,"completionDateStruct":100,"leadSponsor":102,"locationsCount":72},"100547247","phase-2-naliri-xeloxak104-for-first-line-treatment-of-advanced-pdac-100547247","NCT06405490","NALIRI-XELOX+AK104 for First-line Treatment of Advanced PDAC","Nanoliposomal Irinotecan and XELOX (NALIRI-XELOX) in Combination With Cadonilimab for First-Line Treatment of Patients With Locally Advanced or Metastatic Pancreatic Ductal Adenocarcinoma : A Single-arm, Phase II Study","Inclusion Criteria:\n\n1. Age ≥18, male or female;\n2. Has histologically or cytologically confirmed pancreatic ductal adenocarcinoma (PDAC);\n3. Has not received prior systemic treatment for their locally advanced or metastatic PDAC;\n4. Has presence of measurable disease as defined by Response Evaluation Criteria in Solid Tumours (RECIST 1.1);\n5. Has a performance status of 0 or 1 on the Eastern Cooperative Oncology Group (ECOG) Performance Status;\n6. Has a life expectancy of at least 3 months;\n7. Has adequate organ function;\n8. If female of childbearing potential, have a negative serum pregnancy test within 7 days prior to first trial treatment;\n9. If female of childbearing potential or a male subject with a partner with childbearing potential, be willing to use a highly effective method of contraception (with a failure rate of less than 1.0% per year) from first study treatment to 24 weeks after completion of the trial treatment.\n\nExclusion Criteria:\n\n1. Untreated active CNS metastasis or leptomeningeal metastasis.\n2. Is currently participating and receiving an investigational drug or has participated in a study of an investigational drug within 4 weeks or within 5 times of half-life (no less than 2 weeks), whichever is shorter prior to the first dose of trial treatment;\n3. Has received other anti-tumor treatment within 4 weeks or within 5 times of half-life (no less than 2 weeks), whichever is shorter prior to the first trial treatment;\n4. Major surgery for any reason, except diagnostic biopsy, within 4 weeks of the first administration of trial treatment and\u002For if the subject has not fully recovered from the surgery within 4 weeks of the first administration of trial treatment;\n5. Curative radiation within 3 months of the first dose of trial treatment. Radiation to more than 30% of the bone marrow or with a wide field of radiation should not be used within 4 weeks prior to the first administration of trial treatment;\n6. Subjects receiving immunosuppressive agents (such as steroids) for any reason should be tapered off these drugs before initiation of trial treatment (with the exception of subjects with adrenal insufficiency, who may continue corticosteroids at physiologic replacement doses, equivalent to \\\u003C 10 mg prednisone daily, inhaled steroids and topical use of steroids);\n7. Vaccination within 28 days of the first administration of trial treatment, except for administration of inactivated vaccines (e.g., inactivated influenza vaccines);\n8. Has interstitial lung disease, or a history of pneumonitis that required oral or intravenous glucocorticoids to assist with management;\n9. History or current active autoimmune disease that might deteriorate when receiving an immunostimulatory agent；\n10. Previous malignant disease History of uncontrolled intercurrent illness Prior therapy with any antibody\u002Fdrug targeting T cell coregulatory proteins Known severe hypersensitivity reactions to antibody drug；\n11. Is pregnant or breastfeeding;\n12. Other medical conditions that at the discretion of investigator interfere with the requirements of the trial in terms of safety or efficacy evaluation, or treatment compliance.",{"count":81,"type":21},30,[55],"This study is a single-center, Phase II Study to assess the efficacy and safety of the regimen of Nanoliposomal Irinotecan and XELOX (NALIRI-XELOX) in combination with Cadonilimab in subjects with advanced pancreatic ductal adenocarcinoma who have not previously received systemic treatment.",[85,86,31,87,88,89,90,91],"Nanoliposomal Irinotecan","Cadonilimab","Capecitabine","First-Line","Advanced Cancer","Pancreatic Adenocarcinoma","Drug Use",[90,85,86,93,94],"First-Line Treatment","Advanced Pancreatic Adenocarcinoma","2024-12-19",{"date":97,"type":36},"2024-12-24",{"date":99,"type":36},"2024-04-17",{"date":101,"type":21},"2026-12-30",{"name":103,"class":43},"Cancer Institute and Hospital, Chinese Academy of Medical Sciences",{"id":105,"slug":106,"hasResults":11,"nctId":107,"briefTitle":108,"officialTitle":109,"acronym":4,"eligibilityCriteria":110,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":111,"targetDuration":4,"studyType":22,"phases":113,"briefSummary":114,"conditions":115,"keywords":120,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":124,"startDateStruct":126,"completionDateStruct":128,"leadSponsor":130,"locationsCount":72},"100513809","phase-2-xelox-bev-tislelizumab-for-first-line-treatment-of-msspmmr-ras-mutated-mcrc-100513809","NCT05970302","XELOX +Bev +Tislelizumab for First-line Treatment of MSS\u002FpMMR RAS-mutated mCRC","XELOX and Bevacizumab in Combination With Tislelizumab for First-Line Treatment of Patients With MSS\u002FpMMR RAS-mutated Metastatic Colorectal Cancer (mCRC): A Single-arm, Phase II Study.","Inclusion Criteria:\n\n1. Histologically confirmed initially unresectable MSS\u002FpMMR-type RAS-mutant metastatic colorectal adenocarcinoma;\n2. ECOG score of 0 or 1;\n3. Ability to swallow oral medications;\n4. Have at least one measurable lesion (according to RECIST v1.1 standard);\n5. No anti-tumor treatment has been received after recurrence and metastasis;\n6. Neoadjuvant or adjuvant chemotherapy containing fluorouracil drugs is allowed before or after radical resection of colorectal cancer, but the treatment needs to be completed for ≥ 6 months; if oxaliplatin is used in neoadjuvant or adjuvant chemotherapy, it includes The oxaliplatin regimen needs to be completed for ≥12 months;\n7. Adequate organ function: On the premise of no component blood transfusion within 14 days: white blood cells ≥ 3.5\\*10\\^9\u002FL and neutrophils ≥ 1.5\\*10\\^9\u002FL, hemoglobin ≥ 90g\u002FL, platelets ≥ 100\\* 10\\^9\u002FL; serum bilirubin ≤ 1.5 times the normal value, alanine aminotransferase (ALT) ≤ 2.5 times the normal value, aspartate aminotransferase (AST) ≤ 2.5 times the normal value; Urinary protein \\\u003C2+. Or urine protein 2+ but 24-hour urine protein quantity ≤ 1 g; serum creatinine ≤ 1.5 times of normal value, creatinine clearance rate ≥ 60ml\u002Fmin; Doppler ultrasound evaluation: left ventricular ejection fraction (LVEF) ≥ lower limit of normal value (50%);\n8. Expected survival period ≥ 3 months;\n9. Patients fully understand this research, voluntarily participate in this clinical trial and sign an informed consent;\n10. Women with reproductive potential (\\\u003C 2 years after the last menstrual period) and men use effective contraceptive methods until half a year after the last treatment.\n\nExclusion Criteria:\n\n1. Previously received bevacizumab or anti-CTLA4, anti-PD-1\u002FPD-L1 therapeutic antibodies or pathway-targeted drugs;\n2. Received radiotherapy within 4 weeks before the evaluation;\n3. Symptomatic peripheral neuropathy \\> grade 2 (CTCAE5.0 standard);\n4. Received live vaccine or systemic immune stimulant (including but not limited to interferon or interleukin 2) within 1 month;\n5. HIV-positive and other immunodeficiency diseases;\n6. Active hepatitis B or hepatitis C (except for those who have been infected or cured before, that is, HBsAg negative and hepatitis B core antigen anti-HBc antibody positive; except for hepatitis C patients whose HCV RNA is negative by PCR);\n7. Existing autoimmune diseases or other diseases that require immunosuppressant treatment, except for type 1 diabetes; except for hypothyroidism that only requires hormone replacement therapy; skin diseases that do not require systemic treatment (such as vitiligo, psoriasis, alopecia areata); inhaled or topical steroids or equivalent steroids in excess of 10 mg prednisone per day, except for inactive autoimmune disease on adrenal replacement therapy;\n8. Received systemic hormone therapy or treatment with a daily dose of more than 10 mg prednisone equivalent dose or other forms of immunosuppressive treatment within 7 days, but inhaled or topical steroids or daily application of more than 10 mg prednisone, etc. Except for inactive autoimmune diseases treated with adrenal replacement therapy with potent steroids;\n9. Have a history of organ transplantation;\n10. Uncontrolled central nervous system (CNC) metastasis (symptomatic or metastatic sites are midbrain, pons, medulla or spinal cord) or other central nervous system diseases;\n11. Those who have undergone major surgery, open biopsy or obvious traumatic trauma within 1 month, or who may need major surgery during the study period; those who have undergone open biopsy or obvious traumatic trauma, or may need major surgery during the study period;\n12. Combined with other malignant tumors other than intestinal cancer (except cured basal cell carcinoma or squamous cell carcinoma of the skin and carcinoma in situ of the cervix; the treatment of other malignant tumors has been completed for more than 1 year, and there is no clinical and imaging evidence of recurrence or progression except);\n13. Combined active and refractory infection;\n14. Cardiovascular diseases with clinical significance, such as cardiovascular accident (CVA) (≤ 6 months before treatment), myocardial infarction (≤ 6 months before treatment), unstable angina, chronic heart failure of NYHA ≥ 2 (CHF), uncontrolled arrhythmia; uncontrolled hypertension; thromboembolic or bleeding events within 6 months before treatment;\n15. Evidence of causing coagulation disease;\n16. With dysphagia, active peptic ulcer, complete or incomplete intestinal obstruction, active gastrointestinal bleeding, perforation, malabsorption syndrome or uncontrollable gastrointestinal inflammatory disease (such as Crohn's disease or ulcerative colon inflammation);\n17. Severe unhealed wounds\u002Fulcers or severe fractures;\n18. Any serious acute or chronic medical condition that may affect the patient's participation in the study or interfere with the interpretation of the study results;\n19. There are mental illnesses, serious social and psychological illnesses, or researchers believe that there are factors that may affect research compliance;\n20. Pregnant or lactating women;\n21. No therapeutic anticoagulant or antiplatelet drugs or NSAIDs (aspirin ≤ 325 mg\u002Fday allowed);\n22. Severe allergic reaction to the test drug;\n23. Reluctance to use alternative therapies such as (but not limited to) bisphosphonates if receiving RANKL inhibitors (eg, denosumab).",{"count":112,"type":21},52,[55],"The goal of this clinical trial is to compare XELOX +Bev +Tislelizumab with standard chemotherapy，in MSS\u002FpMMR-type RAS-mutated metastatic colorectal adenocarcinoma. The main questions it aims to answer are efficacy and safety of the regimen of XELOX +Bev +Tislelizumab. The investigators want to transform ras-mutated colorectal cancer into a \"hot tumor\" through the combination of anti-vascular therapy and chemotherapy, and then achieve better therapeutic effect through the combination with immunotherapy. Participants will receive the regimen of XELOX +Bev +Tislelizumab.",[60,116,31,87,117,118,119,88],"Bevacizumab","MSS\u002FpMMR","Metastatic Colorectal Cancer (mCRC)","RAS-mutated",[121,122],"Single-arm","Phase II","2023-07-21",{"date":125,"type":36},"2023-08-01",{"date":127,"type":36},"2023-07-07",{"date":129,"type":21},"2026-07",{"name":103,"class":43},{"id":132,"slug":133,"hasResults":11,"nctId":134,"briefTitle":135,"officialTitle":136,"acronym":4,"eligibilityCriteria":137,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":51,"enrollmentInfo":138,"targetDuration":4,"studyType":22,"phases":140,"briefSummary":141,"conditions":142,"keywords":4,"overallStatus":144,"whyStopped":4,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":146,"startDateStruct":148,"completionDateStruct":150,"leadSponsor":152,"locationsCount":4},"100503889","phase-2-tislelizumab-combined-with-chemotherapy-capox-in-the-perioperative-treatment-of-msi-hdmmr-stage-ii-or-iii-colorectal-cancer-100503889","NCT05841134","Tislelizumab Combined With Chemotherapy (CAPOX) in the Perioperative Treatment of MSI-H\u002FdMMR Stage II or III Colorectal Cancer","Multicenter, Single-arm, Open-label Phase II Clinical Study of Tislelizumab Combined With Chemotherapy (CAPOX) in the Perioperative Treatment of MSI-H\u002FdMMR Stage II or III Colorectal Cancer","Inclusion Criteria:\n\n1. ECOG: 0\\~1;\n2. Patients with colon or rectal adenocarcinoma confirmed by histology or cytology;\n3. The tissue specimens are confirmed as MSI-H by PCR or NGS. If the patients are dMMR by immunohistochemistry, they need to be confirmed as MSI-H by PCR (2021 Expert Consensus on Immunotherapy for Patients with Colorectal Cancer);\n4. Patients with clinical stage II or III (cT3-T4 N0 M0 or Tany N+M0, clinically positive lymph nodes are defined as any lymph node ≥ 1.0 cm);\n5. Expected survival period ≥ 12 weeks;\n6. The subjects voluntarily joined the study, signed the informed consent form, had good compliance, and cooperated with follow-up visits.\n\nExclusion Criteria:\n\n1. Have received anti-tumor therapy;\n2. Have received PD-(L)1 or CTLA-4 treatment;\n3. The patient has any active autoimmune disease or has a history of autoimmune disease (such as the following, but not limited to: autoimmune hepatitis, interstitial pneumonia, uveitis, enteritis, hepatitis, hypophysitis, vasculitis, nephritis , hyperthyroidism; patients with vitiligo; asthma that has been completely remitted in childhood and does not require any intervention in adulthood can be included; patients with asthma requiring medical intervention with bronchodilators cannot be included);\n4. Patients are using immunosuppressants or systemic hormone therapy to achieve the purpose of immunosuppression (dose\\>10mg\u002Fday prednisone or other equivalent hormones), and continue to use within 2 weeks before enrollment;\n5. Patients with any severe and\u002For uncontrolled diseases\n6. Urine routine prompts urine protein ≥ ++, and confirmed 24-hour urine protein quantity \\> 1.0g;\n7. Pregnant or lactating women;\n8. Patients with other malignant tumors within 5 years (except cured basal cell carcinoma of the skin and carcinoma in situ of the cervix);\n9. Those who have a history of psychotropic drug abuse and cannot quit or patients with mental disorders;",{"count":139,"type":21},25,[55],"This study is a multi-center, single-arm, open-label phase II clinical trial, aiming to observe and evaluate the perioperative treatment of tislelizumab combined with chemotherapy (CAPOX) in stage II or III colorectal cancer with MSI-H\u002FdMMR Patient efficacy and safety.",[143,60,31,87],"MSI-H Colorectal Cancer","NOT_YET_RECRUITING","2023-05-05",{"date":147,"type":36},"2023-05-09",{"date":149,"type":21},"2023-06-01",{"date":151,"type":21},"2027-01-31",{"name":153,"class":43},"The First Affiliated Hospital of Zhengzhou University"]